Compare Recursion Pharmaceuticals Inc (RXRX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Starbucks Corp trades at $100.5 (market cap $116.29B). The key difference: Starbucks Corp is far larger — about 62.5× Recursion Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SBUX | |
|---|---|---|
Market Cap | $1.86B | $116.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $108.55 |
52-Week Low | $2.84 | $78.46 |
Enterprise Value | $1.38B | $135.12B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Starbucks (SBUX) trades at $102.01, down 2.35% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $37.18B in 2025, though net income margin compressed to 5.17%. The stock faces headwinds from high valuation multiples (P/E 58.97) and negative shareholder equity, but analyst consensus remains positive with a $113.60 price target. Recent news highlights CEO Niccol's turnaround progress and record sales from seasonal offerings.
Outlook is mixed: operational improvements and debt reduction support upside, but margin pressure and union disputes pose risks. The stock offers growth potential if execution continues, yet investors must weigh high valuation against competitive and labor challenges in the coffee retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
